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Abstract
Genetic ablation of endothelial Focal Adhesion Kinase (FAK) can inhibit pathological
angiogenesis, suggesting that loss of endothelial FAK is sufficient to reduce neovascularisation.
Here we show that reduced stromal-FAK expression in FAK-heterozygous mice unexpectedly
enhances both B16F0 and CMT19T tumour growth and angiogenesis. We further demonstrate that
cell proliferation and microvessel sprouting, but not migration, are increased in serum-stimulated
FAK-heterozygous endothelial cells. FAK-heterozygous endothelial cells display an imbalance in
FAK phosphorylation at pY397 and pY861 without changes in Pyk2 or Erk1/2 activity. By
contrast, serum-stimulated phosphorylation of Akt is enhanced in FAK-heterozygous endothelial
cells and these cells are more sensitive to Akt inhibition. Additionally, low doses of a
pharmacological FAK inhibitor, although too low to affect FAK autophosphorylation in vitro, can
enhance angiogenesis ex vivo and tumor growth in vivo. Our results highlight a potential novel
role for FAK as a non-linear, dose-dependent regulator of angiogenesis where heterozygous levels
of FAK enhance angiogenesis.
Introduction
The non-receptor tyrosine kinase, Focal Adhesion Kinase (FAK), can signal downstream of
integrins and growth factor receptors1. FAK is expressed ubiquitously and plays essential
roles in a number of cellular processes, including proliferation and migration, which are
important angiogenic processes. FAK is autophosphorylated at Y397 following integrin
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activation and additionally this site acts to recruit members of the Src-family kinases
(SFKs) 2-4. The proximity of SFKs to FAK is thought to result in its phosphorylation at
other sites, including Y861, and this may cause activation of downstream effectors including
Erk and Akt5,6. Previous reports have highlighted that the kinase activity, and
phosphorylation of FAK at Y397 and Y861, are important regulators of angiogenic
responses in vitro3,7-9. Nonetheless, how the activity of these sites affect the tumour stromal
influence on tumorigenesis has never been addressed.
Genetic studies also have indicated a role for FAK in angiogenesis in vivo. For example, the
global deletion of FAK results in an early embryonic lethal phenotype with defects in the
vascular system10. Constitutive FAK-deletion specifically in vascular endothelial cells (ECs)
caused embryos to die between E10.5 and E13.5, which coincides with the onset of
embryonic vascular system development 11,12, while over-expression of FAK in ECs has led
to enhanced blood vessel density during various angiogenic processes13. Although one
report suggests that the inducible deletion of endothelial-FAK in End-SCL-CreERT adult
mice failed to affect adult angiogenesis, this apparently was because of induced
compensation by a related family member, Pyk214. We have shown previously that
endothelial-specific loss of FAK in Pdgfb-iCreERT2;FAK fl/fl mice inhibit tumour
angiogenesis15. Together these data suggest that loss of FAK can be sufficient to inhibit
pathological angiogenesis. Conversely, although FAK-knockdown inhibited cell migration
and tube formation in vitro10, others have shown that FAK-phosphorylation16 and levels of
expression are decreased during the early stage of an in vitro model of angiogenesis17. Such,
apparently contradicting results suggest that FAK may have non-linear dose dependent roles
in angiogenesis with varied FAK levels differentially affecting angiogenesis. Indeed, the
embryonic development of FAK-heterozygous mice is severely retarded, but these defects
are overcome by birth and FAK-heterozygous mice are born at normal Mendelian ratios
with no gross abnormalities18. In addition, although FAK is expressed ubiquitously, its
expression and activity levels can vary between cells and even within the same cell type4,19,
suggesting that examining the effects of partial loss of endothelial FAK may provide us with
more physiologically relevant information about its roles in vivo.
Here, we have tested the influence that subtle changes in stromal-FAK levels may have on
tumour growth and angiogenesis, by utilising FAK-heterozygous mice20. FAK heterozygous
mice display half the normal levels of FAK protein. We show that FAK-heterozygous mice
exhibit: (1) enhanced B16F0 and CMT19T tumour growth, (2) increased formation of
perfused tumour blood vessels and (3) elevated neovascularisation in vivo. At the molecular
level, we have determined that the ratio of FAK phosphorylation at Y861:Y397 is
misbalanced and that the relative phosphorylation of Akt is elevated in FAK-heterozygous
ECs. In agreement with this, FAK-heterozygous ECs exhibit increased sensitivity to Akt
inhibition. Lastly, low doses of the FAK inhibitor, PF-573228, can phenocopy the responses
in FAK-heterozygotes. Taken together these data suggest that FAK has a non-linear dose
dependent effect in angiogenesis with partial loss of FAK function being sufficient to
enhance pathological angiogenic responses.
Results
Tumour growth and angiogenesis in FAK-heterozygous mice
Tumour growth has been associated with enhanced tumour cell FAK-expression, but the role
of stromal-FAK is less well understood. Although some data indicate that total loss of FAK
can inhibit angiogenic processes 10-12,15, others suggest that it may play a non-linear dose
dependent role in neovascularising events 4,16,17,19. Using FAK-heterozygous mice 20 we
investigated the effect of partial loss of stromal FAK on tumour growth and angiogenesis.
These mice carry only one FAK allele and western blot analysis confirmed that FAK protein
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expression was reduced to 50% in FAK-heterozygous tissues when compared with wild-type
(Supplementary Fig. S1). To assess whether decreased FAK levels play a role in tumour
growth, we injected syngeneic B16F0 melanoma cells or CMT19T lung tumour cells into
the flanks of age- and sex-matched FAK-heterozygous mice and wild-type littermates. Two
weeks post-inoculation, both B16F0 and the CMT19T tumours from FAK-heterozygous
animals were significantly larger than those from wild-type controls (Fig. 1A). Indeed,
tumour growth was increased significantly in FAK-heterozygous mice when compared with
wild-type controls over time (Supplementary Fig. S2). These data indicate that partial loss of
FAK in the tumour stroma is sufficient to enhance tumour growth.
To examine whether the elevated tumour size in FAK-heterozygous mice correlated with
any change in tumour angiogenesis midline sections of size-matched, age-matched tumours
were analysed. Double immunostaining for PECAM and FAK, revealed that endothelial
FAK levels were decreased significantly in tumour blood vessels in FAK-heterozygous mice
when compared with wild-type controls and that the levels varied widely in the wild-type
mice (Supplementary Fig. S3). In contrast, FAK levels were indistinguishable in the tumour
cell compartment between both genotypes suggesting that stromal FAK did not affect
tumour cell FAK levels (Supplementary Fig. S4). Tumour blood vessel density was defined
by counting the total number of blood vessels across entire midline sections and dividing by
the tumour section area. Results revealed that blood vessel density was increased in both
B16F0 and CMT19T tumours grown in FAK-heterozygous mice when compared with
control mice (Fig. 1B). Furthermore, the number of functional, PE-PECAM antibody
perfused, blood vessels was also increased in B16F0 tumours grown in FAK-heterozygous
mice (Fig. 1C). Enhanced tumour blood vessel perfusion has been associated with increased
tumour growth previously 24,25. These data correlated with a significant increase in the
number of BrdU-positive vessels in B16F0 tumours from FAK-heterozygous mice when
compared with those from control mice (Fig. 1D). Importantly the blood vessel density in
unchallenged skin was not changed between genotypes, suggesting that the enhanced
tumour angiogenesis was not due to elevated blood vessel numbers in untreated FAK-
heterozygous mice (Supplementary Fig. S5). Taken together these data point towards a role
for stromal FAK in the regulation of angiogenesis.
Angiogenesis can be affected by various cell types other than ECs. For example, the
formation of stable angiogenic vessels is associated with the recruitment of pericytes. Our
data showed that the number of tumour blood vessels associated with α-smooth muscle
actin-positive pericytes was similar between the two genotypes suggesting that vessel
maturation was not affected by FAK-heterozygosity (Supplementary Fig. S6). Any changes
in tumour vascularity did not appear to correlate with changes in tumour hypoxia, apoptosis,
or levels of serum Vascular Endothelial Growth Factor (VEGF) between the two genotypes
(Supplementary Fig. S7, S8 and S9). Although, changes in inflammatory cell infiltrate have
been reported to enhance neovascularisation26,27 no significant differences in the relative
level of macrophage (Gr1+ or F4/80+) or leukocyte (CD45+) infiltration was observed
between tumours from FAK-heterozygous or control animals (Supplementary Fig. S10).
Overall, although we cannot rule out a non-cell autonomous affect on the enhanced
angiogenesis observed in FAK-heterozygous mice we have no evidence for changes in any
of the cell types tested other than in ECs.
VEGF is a major pro-angiogenic growth factor. To determine whether the changes observed
during tumour angiogenesis could be seen in a tumour free environment, VEGF impregnated
sponges were implanted subcutaneously into FAK-heterozygous and wild-type mice to
stimulate blood vessel growth. Results showed that FAK-heterozygous mice had a higher
infiltration of blood vessels into sponges with or without VEGF when compared with
similarly treated wild-type controls (Fig. 2). Indeed, there was no difference in the fold-
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increase of in vivo blood vessel infiltration in wild-type mice when compared with FAK-
heterozygous mice suggesting that the enhanced angiogenic response was not VEGF-
specific. Thus our data suggested that in vivo VEGF-mediated responses were not enhanced
in FAK-heterozygous mice per se. This notion was corroborated by Western blot analysis
for VEGF-receptor 2 protein expression and downstream signalling activity in purified ECs.
Our results showed that although FAK-heterozygous ECs displayed approximately half the
levels of total FAK, as expected, there was no change in VEGF-stimulated levels of VEGF-
receptor 2, phospho-VEGF-receptor 2, or downstream effectors such as p130Cas, phospho-
p130Cas, total Erk1/2 or phospho-Erk1/2. In short our data indicated that partial loss of
FAK in FAK-heterozygous ECs does not affect VEGF-mediated signalling specifically
(Supplementary Fig. S11). In addition, VEGF-stimulation did not affect the migration speed
of FAK-heterozygous cells (Supplementary Fig. S12). Therefore, although beyond the scope
of the present study, other angiogenic factors may play a role in triggering the enhanced
angiogenic response in FAK-heterozygous mice. Thus we focused on the effect of partial
loss of FAK on serum-stimulated endothelial activity.
FAK-heterozygosity enhances cell survival and tube formation
In order to determine the cellular mechanisms underlying the enhanced pathological
angiogenesis observed in FAK-heterozygous mice, ECs from FAK-heterozygous and
control mice were isolated and subjected to a number of cellular assays. As an indication of
relative survival, ECs grown in full growth medium were assayed for WST-1 metabolism.
Interestingly, FAK-heterozygous ECs demonstrated significantly increased WST-1
metabolism when compared with control cells (Fig. 3A) suggesting that partial loss of FAK
enhances endothelial survival. In contrast, using Dunn chamber assays to determine the
effect of partial FAK loss on cell migration, no statistically significant differences in serum-
mediated migration speed or persistence of cell migration were observed between genotypes
(Fig. 3B).
Tube formation is a vital step of angiogenesis. ECs are known to form tubular structures
when grown on a 2-dimensional (2D) Matrigel™ substrate28. FAK-heterozygous cells
spontaneously formed more tubular structures than wild-type control cells in 2D Matrigel™
assays (Fig. 3C). In addition, in 3-dimensional tubulogenesis assays, FAK-heterozygous
ECs cultured on fibrinogen-coated beads, in the presence of full endothelial growth medium
and a fibroblast feeder layer, developed significantly higher numbers of tubular sprouts than
wild-type cells grown under similar conditions (Fig. 3D). In short, the partial loss of FAK in
ECs confers a spontaneous ability to enhance angiogenic responses that is independent of
effects on EC migration.
Pyk2 does not compensate FAK-heterozygosity
Changes in FAK activity have been correlated with changes in its levels of
phosphorylation 3. In addition, apart from FAK, a related family member, Pyk2 has also
been reported to be expressed in ECs and has, in some circumstances, been implicated in
compensating for FAK 14. We next explored the expression and phosphorylation levels of
FAK and Pyk2 in FAK-heterozygous and wild-type ECs. Immunofluorescence analysis of
total FAK, pY397-FAK, and pY861-FAK showed that, although the intensity levels of total
FAK and pY397-FAK were decreased in the FAK-heterozygous cells (Fig. 4A), the level of
FAK-phosphorylation, specifically at Y861, was similar in FAK-heterozygous and wild-type
ECs (Fig. 4A). Furthermore, western blot analysis of wild-type and FAK-heterozygous EC
extracts confirmed that FAK levels were reduced in FAK-heterozygous ECs, and revealed a
correlation with a decrease in pY397-FAK, but not pY861-FAK levels (Fig. 4B).
Consequently, although the ratio of pY397-FAK/total FAK remained the same between the
two genotypes, the ratio of pY861-FAK/total FAK displayed a two fold increase in FAK-
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heterozygous cells when compared with wild-type ECs. Moreover, a reduction of FAK
levels in ECs did not cause any changes in the expression or phosphorylation of Pyk2 (Fig.
4B). FAK is also known to play an important role in the dynamic regulation of focal
contacts and the organisation of the actin cytoskeleton 2. Our data revealed that FAK-
heterozygosity was not sufficient to alter the organisation of endothelial F-actin bundles
(Fig. 5A). In addition, immunofluorescence and western blot studies suggested that paxillin,
talin and vinculin levels were unchanged between genotypes (Fig. 5A and B). Taken
together, FAK-heterozygosity does not appear to result in overt compensatory mechanisms
involving Pyk2 or other focal contact proteins.
Effect of FAK-heterozygosity on Akt signalling
FAK can affect both integrin and growth factor signalling by regulating downstream targets,
such as Erk1/2 and Akt 1,3,6,8. Our results show that serum-stimulated phosphorylation of
Erk1/2 was not significantly altered in FAK-heterozygous ECs when compared with wild-
type controls. In contrast, although the absolute expression levels of pAkt did not appear to
change between genotypes (Fig 6A), the levels of total Akt were reduced significantly in
FAK-heterozygous ECs compared to wild-type ECs (Supplementary Fig. S13). This resulted
in a significant increase in the ratio of pAkt/ total Akt in FAK-heterozygous ECs when
compared with wild-type controls (Fig. 6A). To establish whether this increase in pAkt/ total
Akt ratio was functionally linked to the increased angiogenic activity of FAK-heterozygotes,
we tested the affect of Akt inhibition on angiogenic responses ex vivo. FAK-heterozygous
and wild-type aortic rings were treated with the Akt inhibitor VIII, which selectively inhibits
the kinase activity of Akt1/2. High doses (10μM range) of the Akt VIII inhibitor were able
to inhibit microvessel sprouting in both FAK-heterozygous and wild-type aortic rings.
However, the enhanced Akt-sensitivity of FAK-heterozygotes was illustrated by their
decreased sprouting response to lower doses (1μM range) of the Akt inhibitor that did not
affect wild-type aortic rings (Fig. 6B). These data suggest that the elevated Akt activation
could contribute to the pro-angiogenic phenotype of FAK-heterozygous mice.
Low-dose FAK inhibition increases tumour growth and angiogenesis
To determine whether inhibition of FAK can enhance microvessel sprouting, we tested the
effect of treatment with various concentrations of FAK inhibitor PF-573228 29 in ex vivo
aortic ring assays. Interestingly, although high concentrations (1μM) of PF-573228 reduced
microvessel sprouting from aortic rings, low concentrations (0.01μM) of the inhibitor
enhanced the numbers of microvessel sprouts significantly (Supplementary Fig. S14),
phenocopying the enhanced angiogenic activity observed in FAK-heterozygous mice.
PF-573228 has not been reported to have been used previously in in vivo experiments.
However, the related PF-562271 FAK inhibitor, that display similar inhibitory activity in in
vitro functional assays29-31, has been shown to inhibit tumour growth in mice at 50mg/kg
dose 30-32. Therefore, we treated wild-type mice bearing B16F0 tumours with 12.5mg/Kg
PF573228 – a suboptimal dose of this inhibitor. Tumour growth was enhanced in mice
treated with 12.5mg/Kg PF573228 compared to placebo treated mice (Supplementary Fig.
S15). Further analysis showed that tumour blood vessel density was also enhanced
significantly in mice treated with 12.5mg/Kg PF573228 (Supplementary Fig. S15). Taken
together these findings indicate that FAK can have a non-linear dose dependent function in
regulating tumour growth and angiogenesis.
Discussion
Although FAK is ubiquitously expressed, its actual levels of expression can vary within
tissues and even within individual cell types4,19. Indeed here we have observed a wide range
of FAK expression levels in ECs from wild-type mice. These observations lead to the
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question of how different levels of FAK might regulate biological outcome - a relatively
unexplored field of research. Some reports have suggested that an increase in FAK within
the whole tumour correlates with tumour progression, but in contrast high levels of FAK do
not always predict outcome3,32-39. Given the emerging importance of the tumour stroma in
regulation of cancer progression, we speculate that the influence of stromal-FAK on tumour
growth may be important. Indeed with the development of FAK inhibitors as potential anti-
cancer drugs40, and the fact that complete pharmacological inhibition of FAK may be
difficult to maintain in vivo, elucidating the effects of different levels of stromal-FAK in
cancer progression becomes a priority41.
Our data show that stromal-FAK heterozygosity is sufficient to enhance tumour growth and
tumour angiogenesis. This does not correlate with any obvious changes in endothelial
expression of focal adhesion proteins or cellular migration, but does correlate with enhanced
EC proliferation and relative Akt activity levels. Thus our results establish a new role for
FAK in the regulation of angiogenesis.
Previous genetic ablation work has highlighted an apparent requirement for FAK during
developmental and postnatal angiogenesis10-12,15. However, in adult organisms the total
deletion of FAK is unlikely to be of physiological relevance. Thus, studying the effect of
reduced levels of FAK may provide us with new information about the roles of this
signalling effector. Our data suggest that heterozygous levels of FAK can elevate angiogenic
responses and our results are corroborated by other reports16,17. For example, FAK-
heterozygous embryos show retarded embryonic development but, by birth, appear
normal18, suggesting that heterozygous levels of FAK might allow for some compensation
that overcomes the embryonic defect. Additionally, in vitro studies have indicated that,
during the first, but not latter, phases of angiogenesis, FAK levels are reduced, suggesting
that FAK may have a non-linear dose-dependent effect in angiogenic processes in vitro16,17.
The tumour stroma consists of various cell types including endothelial cells, smooth muscle
cells/pericytes and inflammatory cells. It is conceivable that the enhanced angiogenic
responses in FAK-heterozygous mice may be due to the up-regulation of some or all of these
non-EC types. However we found no evidence for the increase in the numbers of mural cells
or immune infiltrating cells in tumours grown in FAK-heterozygous mice or the number of
vessels with associated pericytes. Thus, although we cannot rule out a non-cell autonomous
affect here we have focused on the endothelial compartment where have observed FAK-
dependent changes in molecular profiles and EC function.
Our data demonstrate that FAK-heterozygosity is sufficient to affect EC cells, by increasing
endothelial proliferation and sprout formation, but without affecting overall migration speed
of these cells. Pyk2, a member of the FAK family, has been reported previously to
compensate for the loss of FAK14. However we did not observe any changes in Pyk2 levels
or phosphorylation in the FAK-heterozygous ECs. In contrast, in FAK-heterozygous ECs,
although phosphorylation of FAK at Y397 is reduced, the levels of pY861-FAK
surprisingly, remain high. The ratio of pY397/ total FAK remains the same whereas the ratio
of pY861/total FAK is increased. Although it has been proposed that phosphorylation of
Y397 is required for conformational changes that trigger the phosphorylation of Y8615,6,42,
other studies have reported enhanced phosphorylation of Y861-FAK without alterations in
pY397 levels or FAK activity, suggesting that the uncoupling of these two FAK
phosphorylation sites can occur 7,43-45. In addition, FAK-heterozygous ECs have an increase
in both basal and serum-stimulated activation of Akt. Previous genetic studies have
indicated a pro-angiogenic role for Akt 46. More importantly, it has been reported that
sustained activation of Akt in ECs resulted in enhanced blood vessel size and permeability
and increased tumour growth47. Our findings, although correlative, suggest that the
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increased activity of Akt in FAK-heterozygous ECs could be responsible for the enhanced
cellular proliferation and cause elevated angiogenic responses in the FAK-heterozygous
mice. In the ex vivo aortic ring assay, a sub-optimal dose of the Akt VIII inhibitor had a
greater impact on the angiogenic responses of FAK-heterozygotes when compared with
wild-types, suggesting increased sensitivity to Akt inhibition. A recent report demonstrated
that FAK can bind Akt1 independently of the phosphorylation status of Y397 and that
partial depletion of FAK, using siRNA, stimulated basal phosphorylation of Akt48. Thus we
speculate that there may be a link between reduced FAK expression levels, a misbalance of
FAK-phosphorylation and Akt activity that may enhance angiogenic responses.
The mechanisms by which endothelial FAK levels control survival are not clear. It is
tempting to speculate that since FAK has both kinase and non-kinase functions49, and the
non kinase-adaptor functions of FAK can regulate cellular proliferation via p53 without
affecting cell migration18,50, that heterozygous FAK expression may bias for such
scaffolding FAK functions. FAK can also regulate internalisation of surface molecules and
affect cell survival51. Thus, we postulate that signalling downstream of FAK, in FAK-
heterozygous cells, regulates the expression or trafficking of pro-angiogenic cell surface
markers, thereby affecting survival but not migration of these cells. Lastly, other studies
have shown that loss of FAK expression or function can induce a change in Src induced
autophagy and thus enhance cell viability52. Although beyond the scope of this study it
would be of interest to test these ideas in future experiments.
The enhanced angiogenic affect of stromal FAK-heterozygosity raises the possibility that
low doses of FAK inhibitors may phenocopy the response in FAK-heterozygous mice. Our
data indicate that this indeed maybe the case since low doses of FAK inhibitor PF573228
enhanced microvessel sprouting ex vivo, although 0.01μM PF573228 does not appear to
affect autophosphorylation of FAK at Y397 in vitro (unpublished data). Furthermore low
doses of PF573228 increased tumour growth and angiogenesis. We have no evidence that
such low doses prevail when such inhibitors are given at the maximal tolerated doses, where
they have been shown to inhibit tumour growth and angiogenic effects 30-32, or indeed how
low doses may affect the tumour cells themselves. Off target effects of this inhibitor cannot
be excluded or if this applies to other FAK inhibitors. Instead our results reveal new
information about the basic biology behind the role of FAK in angiogenesis and provide
proof-of-principle that reducing stromal-FAK either by genetic ablation or by
pharmacological intervention can elevate angiogenic responses. This work highlights a
novel function of FAK in the regulation of angiogenesis that depends on the levels of FAK
expression, and not simply its presence.
Methods
Primary cell cultures
Primary mouse lung ECs were isolated and cultured as described previously 21 from either
FAK-heterozygous or wild-type control mice. Tissue culture plates for all experiments were
coated with a mixture of collagen (30μg/ml), gelatin (0.1%), and fibronectin (10μg/ml).
In vivo tumour growth
Age- and sex-matched FAK-heterozygous20 and wild-type littermate controls on a mixed
C57BL6/129 background were given a single subcutaneous injection into the flank of either
1 × 106 B16F0 melanoma cells, or 0.5 × 106 CMT19T lung carcinoma cells (ATCC).
Tumour dimensions were measured everyday and the tumour growth was determined using
the formula length × width2 × 0.52. 14 days after injection or when tumour reached the
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maximum legal size allowed, mice were sacrificed; tumour sizes measured, and tumour
samples were either snap-frozen or fixed in 4% paraformaldehyde for histological analysis.
Immunohistochemical analysis
Tumours were bisected and midline sections immunostained for endomucin or PECAM to
detect blood vessels ECs and smooth muscle actin conjugated to Cy3 to detect smooth
muscle cells as described 22. Blood vessel density was calculated by counting the number of
blood vessels per mm2 of midline section. Smooth muscle cell coverage was determined by
calculating the ratio of smooth muscle cell positive blood vessels over total blood vessels15.
Perfused blood vessels were detected by intravenously injection of Phycoerythrin-labelled
PECAM antibody (100μg) 15 min before B16F0 tumour excision. The percentage of
perfused/functional blood vessels was calculated by the ratio of PE-PECAM-positive
perfused vessels over the total blood vessels, detected by staining for endomucin across
whole tumour sections. As a control, transverse sections of unchallenged skin were also
immunostained for endomucin or PECAM and blood vessel density was calculated by
counting the number of blood vessels per mm2 of skin dermis/ section. To examine tumour
ECs proliferation mice received an intraperitoneal injection of 200μl BrdU (5mg/ml) and 30
minutes later were killed and B16F0 tumours were dissected and processed for histological
analysis. Double staining for endomucin and BrdU incorporation was carried out, and
endothelial proliferation was calculated as the number of BrdU positive cells per perimeter
of blood vessels.
Subcutaneous tumour free angiogenesis assay
Briefly, two autoclaved synthetic sponges (a kind gift from Daryl Harmon, Caligen Foam
Ltd.) of approx. 1cm3 in size were implanted subcutaneously in the flanks of anaesthetised
mice. Every 2 days, sponges were injected in situ with either 100μl of PBS alone or 100μl
of PBS containing 10ng/ml VEGF. After 14 days, sponges were excised and fixed for
paraffin embedding. Sections of sponges were immunostained for vWF to identify blood
vessels. Briefly, paraffin sections were dewaxed in xylene, hydrated by sequential
immersion in 100%, 80%, 70% and 50% ethanol solutions and treated with protein kinase
for 15 minutes at 37°C. Sections were blocked with 2% normal goat serum, 1% BSA and
0.1% TritonX-100 and incubated with anti-vWF (AbD Serotec) overnight at 4°C, followed
by a Alexa®-488-conjugated secondary antibody (Invitrogen) for 1 hour at room
temperature. Blood vessel density was assessed by counting the number of vWF-positive
blood vessels/mm2 of sponge section. The nuclear marker DAPI was used as a counterstain.
WST-1 assay
Primary mouse lung ECs were seeded at a density of 2,500 cells/well in coated 96-well
plates. EC medium was changed every 2 days. At each time point, 1 day, 2 days and 4 days,
the cell proliferation reagent, WST-1 (Roche Applied Science) was applied to each well.
Following 3 hours incubation at 37°C, the absorbance of the samples was measured at
450nm using an Anthos 2001 microplate reader. Wells without cells but containing complete
medium and WST-1 acted as baseline absorbance controls. Results were normalised to data
from day 1.
Cell migration Assay
Primary ECs grown on glass coverslips were serum starved for 4 hours in Opti-MEM™.
The coverslips were then placed ‘face-down’ onto Dunn chambers that contained Opti-
MEM™ within the central chamber, and Opti-MEM™ with serum or VEGF in the outer
chamber. Cells were then imaged at the ‘bridge’ between the two chambers, and tracked to
determine speed and persistence of cellular movement.
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2-Dimensional tubulogenesis assay
Primary mouse lung ECs were serum starved for 4 hours in Opti-MEM™. Cells were then
detached from the plate and resuspended in Opti-MEM™ (supplemented with 1% FCS).
50,000 cells were seeded onto solid Matrigel™ (3 wells per condition) in a 48-well plate.
Images of the tubes were recorded using a phase contrast 10x objective lens at 7 hours after
seeding. The area captured by the camera was considered the field of view and 3-4 complete
fields per well were quantified. The total sum length of tube network per field was
quantified.
3-Dimensional endothelial cell sprouting assay
Primary mouse lung ECs were incubated with a suspension of Cytodex™ glass beads (GE
Healthcare) in EGM-2 medium (Lonza) at 37°C for 4 hours with agitation every 20 minutes.
This cell-bead suspension was then plated into flasks and left overnight. The following day,
the coated beads were resuspended gently in 1 mg/ml fibrinogen solution (Invitrogen) with
0.15 units/ml of aprotinin solution (Invitrogen) and transferred to 24-well plates with each
well containing a drop of thrombin solution (Invitrogen). Plates were left at room
temperature for 15 minutes and then placed at 37°C for 1 hour to allow the combined
solution to clot. Finally, mitomycin-inactivated NIH-3T3 fibroblasts were then added to
each well and allowed to settle for 3 hours before changing the medium. Cells were fed with
EGM-2 medium supplemented with 2% FCS with 30ng/ml VEGF or PBS every two days
and sprouts counted daily from day 3 to day 6.
Immunofluorescence of cultured cells
Cells grown on 10-mm glass coverslips were washed once in PBS, fixed in acetone for 5
minutes at −20°C, washed in PBS three times and then blocked with 5% normal goat serum
for 30 minutes at room temperature. After washing the cells once in PBS, cells were
incubated with anti-FAK (1:100, BD-Biosciences cat. no 610087), anti-phospho-FAK
(1:100, Invitrogen cat. no 44624, 44626) and anti-talin (1:100, Sigma T3287) antibodies for
1 hour at room temperature. Alternatively, cells were washed once in PBS, fixed in 4%
paraformaldehyde for 10 minutes, rinsed in PBS, permeabilised in 0.5% NP40 for 10
minutes and blocked with 0.1% BSA/0.2% Triton-X100 for 10 minutes before incubation
with anti-paxillin (1:100 BD-Biosciences 610051), anti-vinculin (1:400 Sigma cat. no
V9131) and Rhodamine-phalloidin for F-actin (1: 1000 Invitrogen R415). Cells were then
washed with PBS and incubated with Alexa-Fluor®-conjugated secondary antibodies
(1:100, Invitrogen) for 45 minutes at room temperature before being mounted on microscope
slides using Prolong® Gold anti-fade reagent (Invitrogen). Fluorescence microscopy was
performed using a CCD camera Hamamatsu C4742-95 and a Zeiss Axioplan microscope.
Identical settings were used to acquire the images in both wild-type and FAK-heterozygous
cells. The mean fluorescent intensity of total FAK, pY397-FAK and pY861-FAK in the
whole cell area was calculated using the ImageJ™ software.
Western blot analysis
For analysis of protein levels, cells were either lysed directly, or serum starved for 4 hours
and then serum-stimulated for 0, 5, 15, 30 and 60 minutes before lysis. Western blot analysis
was performed as described in supplementary methods. The anti-, total FAK, p-Pyk2, total-
Pyk2, p-Erk, total-Erk, p-Akt (Ser473) and total Akt antibodies were from Cell Signaling
Technologies (cat no. 3285, 3291, 3292, 9101, 9102, 9271, 4685, respectively) The
phospho-tyrosine FAK antibodies were from Invitrogen (cat. no. 44626, 44624). The anti-
talin and anti-vinculin were from Sigma-Aldrich (cat no. T3287 and V9131, respectively).
The anti-HSC70 and anti-paxillin were from Santa Cruz Biotechnology (cat. no. sc-24 and
sc-5574). All primary antibodies were used in 1:1000 dilution in 3%BSA or 5% skimmed
Kostourou et al. Page 9
Nat Commun. Author manuscript; available in PMC 2013 December 25.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
milk besides the anti-HSC-70 and the anti-talin that were used in 1:5000 dilution and 1:500
respectively. Densitometric readings of band intensities were obtained using the ImageJ™
software.
Ex vivo aortic ring assay with Akt inhibitor
Thoracic aortas were isolated and prepared for culture as described previously23. Briefly,
1mm thick rings were serum starved for 18 hours at 37°C before being embedded in growth
factor-reduced Matrigel™ (BD Biosciences) and cultured in medium supplemented with
2.5% foetal calf serum (FCS) with or without Akt kinase inhibitor VIII (Calbiochem®,
Millipore), at concentrations indicated. Rings were fed every 2 days with fresh medium
containing 2.5% FCS and the indicated concentration of the inhibitor. Sprouting
microvessels were counted after 6 days.
Ethical regulations
All animal experiments were performed in accordance with UK Home Office regulations
and the European Legal Framework for the Protection of animals used for scientific
purposes (European Directive 86/609/EEC).
Statistical analysis
Statistical significance was calculated with unpaired Student’s t-test and P <0.05 was
considered statistically significant, unless otherwise indicated. For tumour growth statistics,
non-parametric Mann-Whitney U rank sum test was performed to compare tumour volumes
of each day. For Akt inhibition studies of aortic ring sprouting, data is presented using the
log scale for the concentration of Akt inhibitor and statistical analysis between wild-type and
FAK-heterozygous aortic rings at each concentration of Akt inhibitor was performed using
multiple Student’s t-test and P<0.05 was considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Increased tumour size and angiogenesis in FAK-heterozygous mice
(A) Subcutaneous 14 day-old B16F0 and CMT19T tumour sizes were elevated significantly
in FAK-heterozygous (FAK-het) mice when compared with similar tumours in age- and sex-
matched wild-type (WT) control littermates. Top panels, representative images of
macroscopic appearance of tumours. Bar charts represent mean tumour volumes, +s.e.m;
n=20 mice per genotype for the CMTs studies and n=30 mice per genotype for the B16F0
studies, Mann Whitney rank sum test, **P<0.01. (B) Endomucin staining patterns of midline
sections of age-matched, size-matched B16F0 and CMT19T tumours from WT and FAK-het
mice. Microvessel density is given as the number of blood vessels/mm2 of midline tumour
section. Microvessel density in B16F0 and CMT19T tumours was significantly greater in
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FAK-het mice when compared with WT controls. Bar charts represent mean tumour blood
vessel density of age-matched, size-matched tumours + s.e.m. n=20 CMTs tumours and
n=30 B16F0 tumours per genotype, Student’s t-test, **P<0.01, *P<0.06. (C) The number of
functional tumour blood vessels was assessed by i.v. injection of PE-PECAM antibody
before tumour excision in FAK-het and WT control mice. B16F0 tumours grown in FAK-
het mice had an increased number of functional tumour blood vessels compared to WT
littermates. Bar chart represents the % percentage of perfused vessels over total blood
vessels per midline tumour section from WT and FAK-het mice + s.e.m. n=10 tumours per
genotype, Student’s t-test, ***P<0.001. (D) Tumour endothelial proliferation was enhanced
in FAK-het mice. Bar chart represents mean number of BrdU-positive ECs per blood vessel
perimeter length (μm) in midline B16F0 tumour sections from WT and FAK-het mice +
s.e.m. n= 5 tumours per genotype, Student’s t-test, *P<0.04 Scale bars: 0.3cm (A), 30μm
(B).
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Figure 2. Tumour-free angiogenesis is enhanced in FAK-heterozygous mice
Sponges implanted into the flanks of either FAK-het mice or WT controls were injected
with VEGF or PBS every two days for two weeks. At two weeks post implantation, in vivo
angiogenesis was assessed by counting the numbers of blood vessels per mm2 in sponge
sections from WT and FAK-het mice. VEGF-treatment enhanced angiogenesis in both WT
and FAK-het mice. However, quantitation showed that angiogenesis is elevated both at the
baseline level, PBS-treated, (PBS) and after VEGF-stimulation (VEGF) in FAK-het mice.
Upper bar chart represents mean numbers of blood vessels/ mm2 of sponge section + s.e.m.
Lower bar chart shows that the relative fold-increase in microvessel density of FAK-het
mice over WT controls was similar for both PBS and VEGF-treated sponges. Arrowheads
indicate blood vessels. DAPI-stained nuclei, blue, n=7 WT and n=10 FAK-het mice,
Student’s t-test, ns, not statistically significant different, **P<0.05. Scale bar: 100μm.
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Figure 3. Characterisation of endothelial cells isolated from FAK-heterozygous mice
(A) Using the WST-1 assay, primary EC survival in vitro was assessed. Graph shows that,
over 4 days, survival of FAK-heterozygous (FAK-het) ECs was enhanced significantly over
wild-type (WT) EC survival, n=44 wells/condition, 2500 cells/well, Student’s t-test,
**P<0.001. (B) Serum stimulated speed of cell migration and persistence was assessed in
Dunn chambers for WT and FAK-het ECs. No difference in speed or persistence was
detected. Values are given as means + s.e.m. n=57 WT and n=62 FAK-het cells, Student’s t-
test, ns, not statistically significant different. (C) Two-dimensional tube formation (total
tube length) of FAK-het ECs was enhanced significantly when compared with WT cells.
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Upper panels, representative images of endothelial tubes formed by WT and FAK-het
primary ECs on Matrigel™, n=3, Student’s t-test, **P<0.01. (D) Three-dimensional tube
formation of FAK-het ECs was elevated significantly when compared with WT ECs.
Representative images of endothelial sprouts from beads coated with WT and FAK-het cells
cultured on beads in fibroblast-containing fibrin gel. Bar chart represents mean number of
endothelial sprouts per bead + s.e.m., for WT and FAK-het ECs cultured on beads in
fibroblast-containing fibrin gel. Arrows endothelial sprouts. n=54 WT and n=103 FAK-het
beads, 3 independent experiments, Student’s t-test, ***P<0.0005 Scale bars in (C) and (D),
50μm.
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Figure 4. Imbalance between pFAK-Y397 and pFAK-Y861 in FAK-heterozygous cells
(A) Immunocytochemistry for FAK, pY397-FAK and pY861-FAK in cultured wild-type
(WT) and FAK-heterozygous (FAK-het) ECs. Results show that the expression of FAK and
pY397-FAK were reduced in FAK-het cells but that the expression of pY861-FAK was
unchanged. Bar chart represents mean relative fluorescence signal intensity of FAK, pY397-
FAK and pY861-FAK in FAK-het and WT ECs in vitro + s.e.m. n=5, Student’s t-test,
**P<0.01 (B) Western blot analysis of FAK, pY397-FAK, pY861-FAK, Pyk2 and
phosphorylated Pyk2 (pPyk2) in cultured WT and FAK-het ECs lysates. HSC70 acted as a
loading control. Results show that expression levels of total FAK and pY397-FAK are
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similarly reduced in FAK-het cells but that pY861-FAK levels are unchanged between
genotypes, resulting in significantly elevated ratio of pY861-FAK/total FAK while the ratio
of pY397-FAK/total FAK remains the same in FAK-het ECs. The expression of Pyk2 and
the ratio of pPyk2: total Pyk2 are similar in FAK-het and WT ECs. Bar chart represents
densitometric readings relative to WT + s.e.m. n=3 independent experiments, Student’s t-
test **P<0.01, ns, not statistically significant different. Scale bar in (A), 25μm.
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Figure 5. Expression of focal contact proteins in FAK-heterozygous endothelial cells
(A) Immunocytochemistry for F-actin, paxillin, talin and vinculin in cultured wild-type
(WT) and FAK-heterozygous (FAK-het) ECs. (B) Western blot analysis of paxillin, talin
and vinculin in cultured WT and FAK-het EC lysates. HSC70 acted as a loading control.
Results show that overall expression levels of paxillin, talin and vinculin are unchanged
between genotypes. Bar chart represents densitometric readings + s.e.m. n=4 independent
experiments, Student’s t-test, ns, no statistically significant difference. Scale bar in (A),
25μm.
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Figure 6. Effect of FAK heterozygosity on Akt signalling
(A) Western blot analysis of total FAK, phosphorylated-Erk1/2, total Erk1/2,
phosphorylated-Akt and total Akt, in cultured wild-type (WT) and FAK-heterozygous
(FAK-het) EC lysates after serum-stimulation for 0, 5, 15, 30 and 60 mins. HSC70 acted as
loading control. Bar charts show mean densitometric readings of total FAK levels; ratios of
p-Erk1/2:total Erk1/2; and ratios of p-Akt:total Akt from WT and FAK-het EC lysates after
serum-stimulation for 0, 5, 15, 30 and 60 mins,+ s.e.m. n=5 (FAK), n=3 (Erk) and n=4 (Akt)
independent experiments, Student’s t-test, *** P<0.001, **P<0.01, *P<0.05, ns, no
statistically significant difference. (B) Microvessel sprouting of FAK-het aortic rings
displays higher sensitivity to inhibition of Akt activity than WT controls with lower dose of
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Akt inhibitor causing a reduction in microvessel sprouting without affecting wild-type aortic
rings. Bar chart represents the fitting curves of the average number of microvessel aortic
sprouts + s.e.m. relative to the log concentrations of Akt inhibitor VIII. n= 12 aortic rings
per treatment, Student’s t-test, * P< 0.05
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